Zhitong Finance App News, Microchip Biotech (688321.SH) issued an announcement. The company recently received the “Notice of Acceptance” issued by the Drug Evaluation Center of the State Drug Administration for clinical trials of domestically produced drugs. The clinical trial application for CS23546 tablets independently developed by the company for combined treatment of relapsed/refractory lymphoma was accepted.

CS23546 is an oral PD-L1 small molecule inhibitor with a new chemical structure independently developed by the company and protected by global patents. It is a Class 1 new chemical drug. CS23546 has a different target mode of action from antibodies, and has good tumor permeability and selective tumor tissue distribution characteristics.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.